Surrozen Inc
SRZNW0.020USD
0.0000.00%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Surrozen Inc Company
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
Surrozen Inc Info
Ticker SymbolSRZNW
Company nameSurrozen Inc
IPO dateNov 23, 2020
CEOMr. Craig C. Parker
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address171 Oyster Point Blvd
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94080
Phone16504752820
Websitehttps://www.surrozen.com
Ticker SymbolSRZNW
IPO dateNov 23, 2020
CEOMr. Craig C. Parker
Company Executives of Surrozen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Maleki
Mr. Andrew Maleki
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
--
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
--
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
--
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Craig C. Parker
Mr. Craig C. Parker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Mary Haak-Frendscho, Ph.D.
Dr. Mary Haak-Frendscho, Ph.D.
Independent Director
Independent Director
--
--
Dr. Tim W. Kutzkey, Ph.D.
Dr. Tim W. Kutzkey, Ph.D.
Independent Director
Independent Director
--
--
Dr. David J. Woodhouse, Ph.D.
Dr. David J. Woodhouse, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Maleki
Mr. Andrew Maleki
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Charles O. Williams
Mr. Charles O. Williams
Chief Operating Officer, Corporate Secretary
Chief Operating Officer, Corporate Secretary
--
--
Dr. Anna Berkenblit, M.D.
Dr. Anna Berkenblit, M.D.
Independent Director
Independent Director
--
--
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
--
--
Dr. Shao-Lee Lin, M.D., Ph.D.
Dr. Shao-Lee Lin, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Yang Li, Ph.D.
Mr. Yang Li, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
27
2.95M
0.00%
-1.03M
2025Q3
29
3.05M
0.00%
-958.88K
2025Q2
28
3.07M
0.00%
-827.38K
2025Q1
28
3.07M
0.00%
-827.38K
2024Q4
28
2.89M
0.00%
-639.43K
2024Q3
30
2.68M
0.00%
-1.42M
2024Q2
29
4.64M
0.00%
-229.29K
2024Q1
27
4.54M
0.00%
-721.56K
2023Q4
27
4.59M
0.00%
-580.20K
2023Q3
24
5.00M
0.00%
-35.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Monashee Investment Management, LLC
--
0%
-30.13K
-100.00%
Sep 30, 2025
Prelude Capital Management, LLC
--
0%
-24.61K
-100.00%
Jun 30, 2025
Boxer Capital Management, LLC
66.67K
0%
--
--
Sep 30, 2025
Baker Bros. Advisors LP
833.33K
0%
--
--
Sep 30, 2025
LMR Partners LLP
648.28K
0%
--
--
Sep 30, 2025
Bridger Management, LLC
442.05K
0%
--
--
Sep 30, 2025
Euclidean Capital, L.L.C.
170.83K
0%
--
--
Sep 30, 2025
Perceptive Advisors LLC
166.67K
0%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
166.67K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Surrozen Inc?
The top five shareholders of Surrozen Inc are:
Monashee Investment Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Prelude Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Boxer Capital Management, LLC holds 66.67K shares, accounting for 0.00% of the total shares.
Baker Bros. Advisors LP holds 833.33K shares, accounting for 0.00% of the total shares.
LMR Partners LLP holds 648.28K shares, accounting for 0.00% of the total shares.
Monashee Investment Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Prelude Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Boxer Capital Management, LLC holds 66.67K shares, accounting for 0.00% of the total shares.
Baker Bros. Advisors LP holds 833.33K shares, accounting for 0.00% of the total shares.
LMR Partners LLP holds 648.28K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Surrozen Inc?
The top three shareholder types of Surrozen Inc are:
Other
Other
How many institutions hold shares of Surrozen Inc (SRZNW)?
As of 2025Q4, 27 institutions hold shares of Surrozen Inc, with a combined market value of approximately 2.95M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Surrozen Inc?
In --, the -- business generated the highest revenue for Surrozen Inc, amounting to -- and accounting for --% of total revenue.
